Cannabics Pharmaceuticals Inc. (CNBX) Set to Launch Product Cannabics Pharmaceuticals Inc. (CNBX) Set to Launch Product Line in Eligible US States and European Markets
Through its research and development efforts in Israel, Cannabics Pharmaceuticals is focused on developing a wide and deep pipeline of advanced cannabinoid based therapies. As an integral part to its efforts at building shareholder value, CNBX is committed to working with major medical centers in Israel while exploring the beneficial effects of its products in diverse indications.
The company’s core product is Cannabics SR, which is best defined as a sustained release medical cannabis capsule designed for cancer patients as a palliative care treatment. The company’s proprietary SR technology provides ten to twelve hours of steady-state, beneficial therapeutic effects and, as a result, allows for a convenient oral, once-per-day dosing regimen for patients.
Most notably, CNBX is in preparation to launch its line of SR products in eligible US states and EU markets under existing medical cannabis regulatory policies. The company now finds itself in the final stages of planning a series of formal clinical studies that are anticipated to show the medical benefits of its products aimed at patients suffering from a variety of ailments.
Earlier this month, the company confirmed that it had executed an IP Licensing and Collaboration Agreement with Kalapa Holding, a leading medical cannabis provider and distributor in Spain. Kalapa’s offerings include a wide variety of medical cannabinoid based products. The agreement with Kalapa will provide momentum in the production and distribution of Cannabics SR products within the Spanish market.
In strict compliance with Spanish laws and regulations, Cannabics SR medical cannabis products will be available to certified patients only through a regulated Spanish entity and affiliate of Kalapa Holding, the Asociacion Centro Cannabico de Terapias Naturales. The products will be locally manufactured from pure extracts produced from high quality, organic medical cannabis strains by Kalapa’s affiliate, KSK Labs.
Cannabics Pharmaceuticals is focused on developing and marketing sophisticated drugs, therapies, food supplements and administration routes based on the active ingredients found in unique strains of the cannabis plant.
For more information, visit www.cannabics.com
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com